Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684018 · ClinicalTrials.gov registry record · Phase 4
Two Dose Levels of Privigen in Pediatric CIDP
A Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by CSL Behring.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT03684018: Recruiting Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by CSL Behring.
NCT03684018 is a Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03684018, a Phase 4 study of Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Primary Outcome
CIDP relapse, defined as a clinical decline relative to the previous assessment as indicated by an increase in modified Rankin Scale (mRS) of ≥ 1 point, in the Randomized Phase
Conditions Studied
Interventions
- BIOLOGICAL IgPro10
Study Locations (9)
Arizona
- Phoenix Children's Hospital - Phoenix
California
- Children's Hospital of Los Angeles - Los Angeles
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Ohio
- Akron Children's Hospital - Akron
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Le Bonheur Children's Hospital - Memphis
Texas
- Neurology Rare Disease Center - Denton
Virginia
- Children's Specialty Group - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2029-12-20 |
| Phase | Phase 4 |
What NCT03684018 shows while recruiting
NCT03684018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention - of which IgPro10 is the first listed.
NCT03684018 lists 9 locations in 9 states (Arizona, California, Iowa).
Frequently Asked Questions
What is clinical trial NCT03684018 about?
NCT03684018 is a clinical study titled "Two Dose Levels of Privigen in Pediatric CIDP". A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
What is the current status of trial NCT03684018?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2019-02-28. Estimated completion is 2029-12-20.
What conditions does trial NCT03684018 study?
This clinical trial studies the following conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
What interventions are being tested in trial NCT03684018?
The interventions under investigation include: IgPro10 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03684018?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684018 being conducted?
This trial has 9 study locations across Arizona, California, Iowa, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03684018's enrollment target sits among peer trials
30 1552nd of 2000 higher than 368 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI